Citations

Showing 10 of 108119 citations.

Reproducibility of fetal lung‐to‐head ratio in left diaphragmatic hernia across the North American Fetal Therapy Network (NAFTNet)
Abbasi, Nimrah , Ryan, Greg , Johnson, Anthony , Sangi‐Haghpeykar, Haleh , Ye, Xiang Y. , Shah, Prakesh S. , Benachi, Alexandra , Saada, Julien, Ruano, Rodrigo , NAFTNet*, on behalf of the, Papanna, Ramesha , Cortes, Magda Sanz , Benachi, Alexandra , Ruano, Rodrigo , NAFTNet*, on behalf of the, Papanna, Ramesha

Mayo Clinic

Prenatal Diagnosis | January 9, 2019 | Volume: 39 | Issue: 3 | Pages: 188-194

10.1002/pd.5413 | PMID 30618058 Get It

AbstractObjectiveTo determine the antenatal sonographic lung area measurement method in left congenital diaphragmatic hernia (CDH) with the highest interrater agreement among North American Fetal Therapy Network (NAFTNet) centers within and outside the fetoscopic tracheal occlusion (FETO) consortium and in comparison with a European “expert” reviewer (ER).MethodsNineteen members from nine FETO consortium centers and 29 reviewers from 17 non‐FETO centers reviewed ultrasound clips of the chest from 13 fetuses with isolated left CDH and were asked to select a static plane for lung area measurement using anteroposterior (AP), longest, and trace methods. Interrater agreement in lung area measurements was determined using intraclass correlation coefficient (ICC). Bland‐Altman analysis was used to evaluate mean difference (bias) between NAFTNet reviewers and ER.ResultsAmong FETO centers, agreement was highest using trace (ICC 0.94; 95% CI, 0.83‐0.98), followed by longest (ICC 0.89; 95% CI, 0.75‐0.97) and lowest for A‐P (ICC 0.83; 95% CI, 0.67‐0.94). Similar trends were noted in non‐FETO centers. When compared with ER, bias was lowest for trace: 14 ± 38 mm2 and 19 ± 36 mm2 for FETO and non‐FETO centers, respectively.ConclusionThe trace method demonstrated the highest interrater agreement and lowest bias for lung area estimation in left CDH across NAFTNet.
Cigarette smoking is associated with adverse pathological response and increased disease recurrence amongst patients with muscle‐invasive bladder cancer treated with cisplatin‐based neoadjuvant chemotherapy and radical cystectomy: a single‐centre experienc
Soligo, Matteo, Frank, Igor, Boorjian, Stephen A. , Thompson, R. Houston, Tollefson, Matthew K. , Cheville, John C. , Karnes, R. Jeffrey , Thompson, Robert H, Tollefson, Matthew, Quevedo, Fernando J, Karnes, Jeffrey , Boeri, Luca , Quevedo, Fernando

Mayo Clinic

BJU International | January 9, 2019 | Volume: 123 | Issue: 6 | Pages: 1011-1019

10.1111/bju.14612 | PMID 30623554 Get It

Objective To investigate the association between smoking status and pathological response to cisplatin‐based neoadjuvant chemotherapy ( NAC ) and survival outcomes in patients with muscle‐invasive bladder cancer ( MIBC ) treated with radical cystectomy ( RC ). Patients and Methods We reviewed 201 patients treated with NAC and RC for cT 2– cT 4N0M0 BC between 01/1999 and 01/2015. Smoking status was categorised as: ‘never', ‘former', and ‘current' smoker. Pathological response to NAC was defined as: complete (ypT0N0), partial (ypTis/Ta/T1, N0), and no response (ypT2–4 or ypN+). Clinicopathological characteristics were analysed according to smoking status. Logistic regression analyses tested the association between smoking status and pathological response to NAC . Cox regression analyses tested risk factors associated with recurrence, overall ( OM ) and cancer‐specific mortality ( CSM ). Results Overall, there were 58 (28.9%) never smokers, 87 (43.3%) former smokers, and 56 (27.9%) current smokers. No response to NAC was more frequently noted in current smokers (73.2%; P = 0.007). Former smoker ( odds ratio [OR] 2.28; P = 0.024) and current smoker statuses ( OR 4.52; P < 0.001) were significantly associated with no response to NAC , after adjusting for age, gender, Charlson Comorbidity Index, and clinical stage. Similarly, current smoking status ( hazard ratio [HR] 2.14; P = 0.03) and extravesical pathological tumour stage ( HR 3.31; P < 0.001) were independently associated with an increased risk of recurrence after RC . Conclusion Cigarette smoking was significantly associated with adverse pathological response to cisplatin‐based NAC in patients with MIBC treated with RC . Current smokers were at significantly higher risk of disease recurrence as compared to former and never smokers.
Book-Shaped Acellular Fibrocartilage Scaffold with Cell-loading Capability and Chondrogenic Inducibility for Tissue-Engineered Fibrocartilage and Bone–Tendon Healing
Chen, Can , Liu, Fei , Tang, Yifu , Zheng, Cheng , Chen, Yang , Li, Muzhi , Zhao, Chunfeng , Sun, Lun‐Quan , Lü, Hongbin , Zheng, Cheng , Chen, Yang , Li, Muzhi , Lu, Hongbin , Qu, Jin , Cao, Yong Bing , Hu, Jianzhong

Mayo Clinic

ACS Applied Materials & Interfaces | January 9, 2019 | Volume: 11 | Issue: 3 | Pages: 2891-2907

10.1021/acsami.8b20563 | PMID 30620556 Get It

Not All Cellular Rejections Are the Same: Differences in Early and Late Hepatic Allograft Rejection
Morgan, Paige , Nehra, Avinash , Hathcock, Matthew , Kremers, Walter K. , Wiesner, Russell H., Taner, Timuçin , Morgan, Paige E, Nehra, Avinash K, Hathcock, Matthew A, Taner, Timucin , Kremers, Walter K , Jadlowiec, Caroline C. , Morgan, Paige E., Heimbach, Julie K.

Mayo Clinic

Liver Transplantation | January 8, 2019 | Volume: 25 | Issue: 3 | Pages: 425-435

10.1002/lt.25411 | PMID 30615251 Get It

T cell–mediated rejection (TCMR) is common after liver transplantation (LT), and it is often thought to have a minimum impact on outcomes. Because alloimmune response changes over time, we investigated the role of the timing of TCMR on patient and allograft survival and examined the risk factors for early and late TCMR. We reviewed protocol liver biopsies for 787 consecutive LT recipients with an 8.6‐year follow‐up. The incidence of early TCMR (≤6 weeks after LT) was 33.5% with nonalcoholic steatohepatitis patients having the lowest incidence. Younger recipient age (P < 0.01), number of human leukocyte antigen mismatches (P < 0.01), and use of deceased donor allografts (P = 0.01) were associated with increased risk of early TCMR, which had no impact on allograft (hazard ratio [HR], 1.02; 95% CI, 0.79‐1.32; P = 0.89) or overall survival (HR, 1.03; 95% CI, 0.78‐1.34; P = 0.86). Late TCMR (>6 weeks after LT) was less common (17.7%) and was associated with different risk factors. The majority of late TCMR (56.2%) episodes had no antecedent early TCMR, although moderate‐to‐severe early TCMR (HR, 2.85; 95% CI, 1.55‐5.23; P < 0.01) and steroid resistance (HR, 3.62; 95% CI, 1.87‐6.99; P < 0.01) were associated with late TCMR. Late TCMR increased risk of mortality (HR, 1.89; 95% CI, 1.35‐2.65; P = 0.001) and graft loss (HR, 1.71; 95% CI, 1.23‐2.37; P = 0.001). Thus, these data suggest that the timing and histologic grade of TCMR determine its impact on patient and allograft survival. Early mild TCMR episodes after LT do not adversely impact patient or allograft survival provided that they are adequately treated. The occurrence of late TCMR carries deleterious effects with increased longterm risk of graft loss and decreased survival. Patients with moderate‐to‐severe early TCMR are at an increased risk for late TCMR and warrant closer clinical follow‐up.
Efficacy of chest computed tomography prediction of the pathological TNM stage of thymic epithelial tumours†
White, Darin , Hora, Megan J, Jenkins, Sarah M. , Marks, Randolph S., Garces, Yolanda I. , Cassivi, Stephen D. , Roden, Anja C. , White, Darin B

Mayo Clinic

European Journal of Cardio-Thoracic Surgery | January 8, 2019 | Volume: 56 | Issue: 2 | Pages: 285-293

10.1093/ejcts/ezz013 | PMID 30753469 Get It

Abstract OBJECTIVES The aim of this study is to evaluate the efficacy of chest computed tomography (CT) to predict the pathological stage of thymic epithelial tumours (TET) using the recently introduced tumour, node and metastasis (TNM) staging with comparison to the modified Masaoka staging. METHODS Preoperative chest CT examinations in cases of resected TET with sampled lymph nodes (2006–2016) were retrospectively reviewed by 2 thoracic radiologists and radiologically (r) staged using both staging systems. A thoracic pathologist reviewed all cases for the pathological (p) stage. Concordance between r-staging and p-staging was assessed by % agreement and unweighted kappa statistics. Associations between r-stage and p-stage with outcomes were assessed using the Cox proportional hazards regression. RESULTS Sixty patients with TET were included (47 thymomas, 12 thymic carcinomas and 1 atypical carcinoid tumour). Sixteen patients (26.7%) had received neoadjuvant therapy. Fifty-four patients (90.0%) had complete resection. The overall agreement between the r-stage and p-stage was 66.7% (κ = 0.46) for TNM staging and 46.7% (κ = 0.30) for modified Masaoka staging. Agreement between r-assessment and p-assessment of the T, N and M components of the TNM stage was 61.7% (κ = 0.28), 86.7% (κ = 0.48) and 98.3% (κ = 0.88), respectively. CT overstaged 12 patients (20.0%) for TNM staging and 12 patients (20.0%) for modified Masaoka staging and understaged 8 (13.3%) and 20 (33.3%) patients for TNM staging modified Masaoka staging, respectively. The r-TNM staging accuracy was lower for patients with neoadjuvant therapy (50.0% with vs 72.7% without). During a median follow-up of 2.6 years (range 0.1–10.5 years), 12 patients had metastases and/or recurrence; 11 patients died (4 of disease). The r-TNM stage and modified Masaoka stage were associated with overall survival and progression-free survival (P < 0.001). CONCLUSIONS Preoperative chest CT is able to accurately predict p-TNM stage in two-thirds of surgically resected TET, with an agreement between radiological staging and pathological staging superior to the modified Masaoka staging.
Editorial: a new era in anti-neutrophil cytoplasmic antibody vasculitis
Fouque, Denis , Fervenza, Fernando C.

Mayo Clinic

Nephrology Dialysis Transplantation | January 8, 2019 | Volume: 34 | Issue: 3 | Pages: 379-381

10.1093/ndt/gfz002 | PMID 30834449 Get It

Superior Oblique Palsy: Efficacy of Isolated Inferior Oblique Recession in Cases with Ipsilateral Hypertropia in Abduction
Torrado, Laura A. , Brodsky, Michael C.

Mayo Clinic

Journal of Binocular Vision and Ocular Motility | January 8, 2019 | Volume: 69 | Issue: 1 | Pages: 8-12

10.1080/2576117x.2018.1554931 | PMID 30615559 Get It

Nivolumab for Relapsed/Refractory Diffuse Large B-Cell Lymphoma in Patients Ineligible for or Having Failed Autologous Transplantation: A Single-Arm, Phase II Study
Ansell, Stephen M. , Johnson, Peter , Timmerman, John M. , Armand, Philippe , Ligon, Azra H. , Roemer, Margaretha G.M., Reddy, Nishitha , Cohen, Jonathon B. , Poon, Michelle, Kato, Kazunobu, Samakoglu, Selda, Sumbul, Anne, Grigg, Andrew , Johnson, Peter , Minnema, Monique C , Shipp, Margaret Ann , Rodig, Scott J , Roemer, Margaretha G.M. , Assouline, Sarit E. , Sharma, Manish R.

Mayo Clinic

Journal of Clinical Oncology | January 8, 2019 | Volume: 37 | Issue: 6 | Pages: 481-489

10.1200/jco.18.00766 | PMID 30620669 Get It

Purpose Treatment options are limited for patients with relapsed/refractory diffuse large B-cell lymphoma (DLBCL). Tumor cells can exploit the programmed death-1 checkpoint pathway to evade immune surveillance. In the current study, we evaluated the efficacy and safety of programmed death-1 blockade by nivolumab in patients with relapsed/refractory DLBCL. Methods In this phase II, open-label study, patients with relapsed/refractory DLBCL who were ineligible for autologous hematopoietic cell transplantation (auto-HCT) or who had experienced failure with auto-HCT received nivolumab 3 mg/kg every 2 weeks. We assessed the efficacy and safety of nivolumab as well as genetic alterations of 9p24.1. Results Among 121 treated patients, patients in the auto-HCT–failed cohort (n = 87) received a median of four nivolumab doses and a median of three doses were administered to those in the auto-HCT–ineligible cohort (n = 34). At a median follow-up of 9 months in the auto-HCT–failed cohort and 6 months in the auto-HCT–ineligible cohort, independently assessed objective response rates were 10% and 3%, and median durations of response were 11 and 8 months, respectively. Median progression-free survival and overall survival were 1.9 and 12.2 months in the auto-HCT–failed cohort and 1.4 and 5.8 months in the auto-HCT–ineligible cohort respectively. All three patients with complete remission—3% of the auto-HCT–failed cohort—had durable response (11 or more, 14 or more, and 17 months). Treatment-related grade 3 and 4 adverse events were reported in 24% of patients. The most common were neutropenia (4%), thrombocytopenia (3%), and increased lipase (3%). Of all evaluable samples for 9p24.1 analysis, 16% exhibited low-level copy gain and 3% had amplification. Conclusion Nivolumab monotherapy is associated with a favorable safety profile but a low overall response rate among patients with DLBCL who are ineligible for auto-HCT or who experienced failure with auto-HCT. Genetic alterations of 9p24.1 are infrequent in DLBCL.
Squamous Cell Carcinoma in Perineal, Perianal, and Gluteal Hidradenitis Suppurativa: Experience in 12 Patients
Kohorst, John J. , Shah, Kabeer , Hallemeier, Christopher L. , Baum, Christian L. , Davis, Mark D. P. , Hallemeier, Christopher Leigh , Davis, Mark D.P.

Mayo Clinic

Dermatologic Surgery | January 8, 2019 | Volume: 45 | Issue: 4 | Pages: 519-526

10.1097/dss.0000000000001713 | PMID 30608295 Get It

BACKGROUND Few reports describe squamous cell carcinoma (SCC) arising in hidradenitis suppurativa (HS). OBJECTIVE The 2 objectives were (1) to describe the clinical characteristics, pathologic findings, and postoperative outcomes of SCC in HS and (2) to assess whether human papillomavirus (HPV) is involved in the pathogenesis. MATERIALS AND METHODS Cases of SCC in HS were identified through institutional medical records (1976–2013) and the Rochester Epidemiology Project. Tumor specimens were assessed for HPV DNA/RNA with in situ hybridization. RESULTS Twelve patients were identified (11 Caucasians and 9 men). All SCCs involved gluteal, perianal, or perineal skin; 1 patient had, in addition, involvement of the vagina. Surgical excision was performed on all 12 patients, 4 of whom had a colostomy. Mean duration of HS before SCC development was 28.5 years (range, 15–53 years). Mean follow-up was 4.3 years after surgical excision. Seven of 12 patients followed had postoperative SCC recurrence. Squamous cell carcinoma caused death despite wide surgical excision in these 7 patients. Of the remaining 5 patients, 4 are unknown and 1 who did not recur had an in situ SCC (Bowen disease carcinoma). Squamous cell carcinoma was not associated with high-risk or low-risk HPV. CONCLUSION Invasive SCC arising in HS carries a high risk of death.